Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 2011 94 St NW Suite 101 EDMONTON AB T6N 1H1 |
Tel: | N/A |
Website: | https://innovotech.ca |
IR: | See website |
Key People | ||
James Timourian Chairman of the Board, President, Chief Executive Officer, Company Secretary | Alan C. Savage Chief Financial Officer, Director |
Business Overview |
Innovotech Inc. is a Canada-based biotechnology company. The Company is engaged in owning intellectual property, conducting contract research, and owning and providing devices for testing in multiple applications in microbiology. Its contract research services include Antimicrobial Contract Research; Antimicrobial and Anti-Biofilm Agents, including Minimum Inhibitory Concentration (MIC) and Minimum Biofilm; Eradication Concentration (MBEC); Antimicrobial and Anti-Biofilm Materials, including TM100, ISO 22196 and USP 51; Customized Antimicrobial Testing, including BEST Assay Testing and Implanted Medical Device Testing; Bacteriophage Testing; and Analytical Capabilities. It also offers MBEC Assay Kits, Order Biofilm Assays and Coated MBEC Assay Lids. Its biofilm research includes The Science of Biofilms, Biofilm Publications and SEM Library. Its antimicrobial silver products include AgreGuard-1 Silver Antimicrobial for Crop Protection and InnovoSIL Antimicrobial Silver Products. |
Financial Overview |
For the nine months ended 30 September 2023, Innovotech Inc revenues decreased 4% to C$842K. Net loss increased from C$53K to C$128K. Revenues reflect Rest Of World segment decrease of 18% to C$88K, Canada segment decrease of 36% to C$20K. Higher net loss reflects General and Administrative increase of 14% to C$704K (expense), Sales and Marketing increase from C$1K to C$24K (expense). |
Employees: | 16 as of Mar 13, 2012 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $3.78M as of Sep 30, 2023 |
Annual revenue (TTM): | $1.09M as of Sep 30, 2023 |
EBITDA (TTM): | -$0.18M as of Sep 30, 2023 |
Net annual income (TTM): | -$0.21M as of Sep 30, 2023 |
Free cash flow (TTM): | -$0.26M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 39,003,612 as of Feb 6, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |